GEN-003: Additional Phase I/IIa data

Additional data from a double-blind, placebo-controlled, dose-escalation, U.S. Phase I/IIa trial in 143 patients with moderate to severe HSV-2 infection who were otherwise healthy showed that GEN-003 containing 30 µg each of ICP4 and gD2 reduced the number of clinical lesion days at 6 months by 72% compared to baseline (p<0.001).Additionally, Genocea said the 50% reduction from baseline in mean viral shedding that was observed at day 71 was maintained at 6 months following the 3 doses of GEN-003 (p<0.001). Data were presented at the World Vaccine Congress in Washington D.C. ...